Evogene (EVGN) Other Operating Expenses (2012 - 2026)
Evogene (EVGN) posted Other Operating Expenses of $359000.0 for Q1 2026, down 30.56% sequentially from $517000.0 in Q4 2025, and up 74.27% YoY from $206000.0 in Q1 2025.
Evogene (EVGN) Other Operating Expenses (2012 - 2026) Analysis & Trends
Evogene has reported Other Operating Expenses for 15 years, with the latest figure at $359000.0 in Q1 2026.
- Quarterly Other Operating Expenses rose 74.27% year-over-year to $359000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 653.85% YoY) and the FY2025 annual result came in at $2.2 million, up 524.12% from the prior year.
- Other Operating Expenses retreated to $359000.0 in Q1 2026 per EVGN's latest filing, from $517000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $1.0 million in Q3 2024 and troughed at -$2.3 million in Q4 2022.
- A 5-year average of $167000.0 and a median of $359000.0 in 2026 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Other Operating Expenses sank 4092.31% in 2024, then soared 8140.0% in 2025.
- Over 5 years, Other Operating Expenses stood at -$2.3 million in 2022, then soared by 101.11% to $26000.0 in 2023, then tumbled by 4092.31% to -$1.0 million in 2024, then soared by 149.81% to $517000.0 in 2025, then plunged by 30.56% to $359000.0 in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $359000.0, $517000.0, and $378000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 359,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Sep 30, 2025 | 378,000.00 |
| Jun 30, 2025 | 412,000.00 |
| Mar 31, 2025 | 206,000.00 |
| Dec 31, 2024 | -1.04 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 519,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Sep 30, 2023 | -26,000.00 |
| Jun 30, 2023 | 26,000.00 |
| Mar 31, 2023 | -26,000.00 |
| Dec 31, 2022 | -2.33 Mn |
| Sep 30, 2022 | 895,000.00 |
| Jun 30, 2022 | 962,000.00 |
| Mar 31, 2022 | 908,000.00 |
| Dec 31, 2021 | 720,000.00 |
| Sep 30, 2021 | 776,000.00 |
| Jun 30, 2021 | 672,000.00 |